Malalis, John Michael R.
HRN: 22-01-22 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/25/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
09/25/2022
10/02/2022
IV
42mg
Q24h
Potentially Septic Newborn (Thinly Msaf)
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes